Midmichigan Medical Ctr
- Type
- Teaching hospital
- Where
- MIDLAND, MI
- Medicare CCN
- 230222
- Received
- $681,428 in 78 records, 2024 ($32,575 general, $648,853 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 39 | $32,575 |
| 2024 | Research payment | 39 | $648,853 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 2 | $560,701 | 2024 |
| Dompe Farmaceutici S.p.A. | 25 | $45,687 | 2024 |
| Tandem Diabetes Care, Inc. | 30 | $22,350 | 2024 |
| CSL Behring | 5 | $14,005 | 2024 |
| AstraZeneca UK Limited | 1 | $13,560 | 2024 |
| Abbott Laboratories | 3 | $8,198 | 2024 |
| Medtronic, Inc. | 4 | $6,325 | 2024 |
| AstraZeneca Pharmaceuticals LP | 1 | $5,200 | 2024 |
| Stryker Corporation | 2 | $2,745 | 2024 |
| SANOFI US SERVICES INC. | 2 | $1,500 | 2024 |
| Smith+Nephew, Inc. | 1 | $1,000 | 2024 |
| Thermo Fisher Scientific Asheville LLC | 1 | $103 | 2024 |
| Teleflex LLC | 1 | $50 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 39 | $648,853 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 34 | $28,675 |
| Long term medical supply or device loan | 3 | $2,796 |
| Space rental or facility fees (teaching hospital only) | 1 | $1,000 |
| Debt forgiveness | 1 | $103 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Stryker Corporation | $1,553 | Long term medical supply or device loan | In-kind items and services | PROCUITY Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,192 | Long term medical supply or device loan | In-kind items and services | PROCUITY Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | Teleflex LLC | $50 | Long term medical supply or device loan | In-kind items and services | WECK Device, SURGICAL | 2024 | |
| 2024-12-10 | Smith+Nephew, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ALLEVYN HEEL 10.5CM X 13.5CM CTN 5 Device, Exudate Management | 2024 | |
| 2024-12-06 | Medtronic, Inc. | $1,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MINIMED 780G Device, Durable Pump | 2024 | |
| 2024-12-04 | Tandem Diabetes Care, Inc. | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-11-15 | Abbott Laboratories | $2,500 | Research payment | Cash or cash equivalent | NAVITOR Device, VASCULAR | Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients Who Have Severe, Symptomatic, | 2024 |
| 2024-11-15 | Abbott Laboratories | $198 | Research payment | Cash or cash equivalent | NAVITOR Device, VASCULAR | Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients Who Have Severe, Symptomatic, | 2024 |
| 2024-11-13 | Tandem Diabetes Care, Inc. | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-11-06 | Tandem Diabetes Care, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-10-23 | Tandem Diabetes Care, Inc. | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-10-17 | Abbott Laboratories | $5,500 | Research payment | Cash or cash equivalent | NAVITOR Device, VASCULAR | Envision IDE Study | 2024 |
| 2024-10-02 | Tandem Diabetes Care, Inc. | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-10-02 | Dompe Farmaceutici S.p.A. | $1,293 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-10-02 | Dompe Farmaceutici S.p.A. | $941 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-10-02 | Dompe Farmaceutici S.p.A. | $941 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-10-02 | Dompe Farmaceutici S.p.A. | $812 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-10-02 | Dompe Farmaceutici S.p.A. | $726 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-10-02 | Dompe Farmaceutici S.p.A. | $289 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-09-25 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-09-18 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-09-11 | Tandem Diabetes Care, Inc. | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-09-11 | Dompe Farmaceutici S.p.A. | $750 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-09-11 | Dompe Farmaceutici S.p.A. | $500 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-09-06 | Medtronic, Inc. | $2,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MINIMED 780G Device, Durable Pump | 2024 | |
| 2024-08-28 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-21 | Tandem Diabetes Care, Inc. | $350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-14 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-07 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-05 | Dompe Farmaceutici S.p.A. | $750 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-08-02 | Dompe Farmaceutici S.p.A. | $5,000 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-07-31 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-07-24 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-07-05 | SANOFI US SERVICES INC. | $750 | Research payment | Cash or cash equivalent | An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity | 2024 | |
| 2024-06-26 | Tandem Diabetes Care, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-06-20 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-06-17 | Medtronic, Inc. | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MINIMED 780G Device, Durable Pump | 2024 | |
| 2024-06-12 | Dompe Farmaceutici S.p.A. | $2,500 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-06-05 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-05-30 | Thermo Fisher Scientific Asheville LLC | $103 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-05-22 | CSL Behring | $10,005 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-05-16 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-26 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-04-26 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-04-25 | SANOFI US SERVICES INC. | $750 | Research payment | Cash or cash equivalent | An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity | 2024 | |
| 2024-04-24 | Tandem Diabetes Care, Inc. | $1,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-17 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | $12,500 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | $2,843 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | $2,843 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | $1,912 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | $1,895 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | $1,789 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | $1,327 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | $1,000 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-10 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | $602 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | $500 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | $50 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | $500 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-03 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-03-22 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-22 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-21 | Medtronic, Inc. | $2,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MINIMED 780G Device, Durable Pump | 2024 | |
| 2024-03-20 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-03-13 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-03-06 | Tandem Diabetes Care, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-02-21 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-02-08 | Tandem Diabetes Care, Inc. | $1,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-02-01 | Novartis Pharmaceuticals Corporation | $65,424 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2024 |
| 2024-01-26 | Dompe Farmaceutici S.p.A. | $3,252 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-01-17 | Tandem Diabetes Care, Inc. | $1,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-01-10 | Novartis Pharmaceuticals Corporation | $495,277 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2024 |
| 2024-01-10 | AstraZeneca UK Limited | $13,560 | Research payment | Cash or cash equivalent | A Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MED | 2024 | |
| 2024-01-10 | Tandem Diabetes Care, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-01-04 | Dompe Farmaceutici S.p.A. | $172 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-01-03 | AstraZeneca Pharmaceuticals LP | $5,200 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin in Acute Decompensated Heart Failure | 2024 |
| 2024-01-03 | Tandem Diabetes Care, Inc. | $850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Midland, MI, county Midland County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Midland, MI | County Midland County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 42,724 | 83,757 | 10,077,761 |
| Population, 2020 census P1 | 42,547 | 83,494 | 10,077,331 |
| Median age B01002 | 39.3 | 41.8 | 40.2 |
| Under 18 B01001 | 21.2% | 20.9% | 21.2% |
| 65 and over B01001 | 20.4% | 20.2% | 18.6% |
| Households B11001 | 18,535 | 34,993 | 4,076,369 |
| Foreign born B05002 | 4.8% | 3.2% | 7.2% |
| Median household income B19013 | $73,325 | $77,705 | $72,875 |
| Median family income B19113 | $103,505 | $100,943 | $93,357 |
| Per capita income B19301 | $44,053 | $43,622 | $40,735 |
| Poverty rate B17001 | 10.3% | 10.7% | 13.2% |
| Unemployment rate B23025 | 4.1% | 4.4% | 5.7% |
| Civilian labor force B23025 | 20,510 | 40,590 | 5,018,449 |
| Mean commute (minutes) B08013 | 20.0 | 23.7 | 24.2 |
| Bachelor's degree or higher B15003 | 44.6% | 36.6% | 32.4% |
| Housing units B25001 | 19,459 | 37,160 | 4,622,236 |
| Owner-occupied B25003 | 67.1% | 78.1% | 73.2% |
| Renters B25003 | 32.9% | 21.9% | 26.8% |
| Median home value B25077 | $203,900 | $195,400 | $231,600 |
| Median gross rent B25064 | $1,048 | $1,016 | $1,129 |
| White, not Hispanic B03002 | 86.3% | 89.2% | 72.4% |
| Black B03002 | 2.0% | 1.2% | 13.1% |
| Hispanic or Latino B03002 | 4.6% | 3.4% | 5.9% |
| Asian B03002 | 3.3% | 2.2% | 3.4% |
| American Indian and Alaska Native B03002 | 0.0% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Midland, MI.
Comments